An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).

Joan CarlesAngelika PichlerHana KorunkovaAntoaneta TomovaMarwan GhosnFadi El KarakJoseph MakdessiIrina KorolevaGisoo BarnesDenise BuryAyse ÖzatilganSimon HitierJana Katolicka

Published in: BJU international (2018)

Patients in CAPRISTANA treated with cabazitaxel had similar disease outcomes and safety profiles compared with large phase III clinical trials. Most patients had maintained or improved HRQoL scores; >70% of patients had maintained or improved pain control.

Keyphrases

end stage renal disease
newly diagnosed
clinical trial
ejection fraction
chronic kidney disease
prognostic factors
squamous cell carcinoma
chronic pain
open label
patient reported outcomes
metabolic syndrome
pain management
cross sectional
insulin resistance
study protocol